Company announcements from OncoFirm Diagnostics.
New York, NY — August 3, 2026. OncoFirm™ Diagnostics Corporation announced that it has filed six patent applications and three trademark applications relating to the diagnostic technologies it is developing….
AI-Driven Biomarkers: The Future of Precision Diagnostics Unlocking the Invisible Signals of Health In a world where early detection saves lives, AI-driven biomarkers are revolutionizing how we understand, monitor, and…
Researchers applied MIGHT to liquid biopsy data, focusing on ccfDNA fragmentation patterns (e.g., fragment lengths, positions, and end motifs) to determine which features reliably indicate cancer: Challenge: False Positives Linked…
Biochemical diagnostics is the branch of laboratory medicine that uses chemical and biochemical tests to detect, measure, and interpret changes in the body’s biochemical processes for the purpose of diagnosing…
Mission: OncoFirm Diagnostics: Rapid Cancer Screening, Empowering public health systems worldwide with fast, accurate, and affordable cancer diagnostics—delivered wherever they are needed most. Why Early Detection Matters: Cancer is a…
Our primary corporate website is now OncoFirm.com.
Visit our main website for the latest information about our cancer diagnostic technologies, research programs, intellectual property, corporate developments, partnerships and investor opportunities.
Continue to OncoFirm.com